Seattle Genetics, the developer of targeted cancer drugs, said today it has hired Elaine Waller as senior vice president in charge of regulatory affairs. The Bothell, WA-based company (NASDAQ: [[ticker:SGEN]]) has some big meetings on the docket with U.S. regulators this fall, as it prepares its plan for a pivotal clinical trial of SGN-35 for Hodgkin’s disease. Waller has 20 years’ experience in regulatory affairs, most recently with Bothell, WA-based Sonus Pharmaceuticals.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
